Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study aims to evaluate the annual effective dose from a sleeping mattress containing naturally occurring radioactive material (NORM). In this study, the dose rate was measured using two different portable radiation detectors, namely the Geiger Müller (GM) tube and portable high-purity germanium (HPGe) detector; the annual effective dose was calculated using annualized usage of the products, and the equivalent does was evaluated via Monte Carlo (MC) simulation and using the model of the human body, which is known as a computational human phantom. The dose rate of the product, excluding background radiation at the shielded room, was measured as 0.22 and 0.13 μSv/h in the GM-tube and portable HPGe, respectively. Assuming that the sleeping mattress was used for an average sleeping of 8 h/day, the annual effective dose was calculated as 0.64 and 0.38 mSv/y using the GM-tube and portable HPGe detectors, respectively. Also, the annual effective dose calculated using MC simulation and radioactivity values from the nuclides analysis was 0.13 mSv/y. The annual effective dose calculated using the two different portable detectors and MC simulation is less than the annual effective dose limit for the general public, which is set at 1 mSv/y. This technique could be used not only for the safety regulation for products containing NORM but also for the accurate evaluation of the effective dose for radiation workers in the diverse radiation field.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.apradiso.2019.108860 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combinatorial targeting of PI3K/AKT pathway with BKM120 increases cisplatin sensitivity and apoptotic response in A549 lung cancer cells.
Cell Mol Biol (Noisy-le-grand)
September 2025
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Despite significant advancements in the treatment of non-small cell lung cancer (NSCLC) using conventional therapeutic methods, drug resistance remains a major factor contributing to disease recurrence. In this study, we aimed to explore the potential benefits of combining PI3K inhibition with Cisplatin in the context of NSCLC-derived A549 cells. Human non-small cell lung cancer A549 cells were cultured and treated with BKM120, cisplatin, or their combination.
View Article and Find Full Text PDFPatient Preferences and Understanding of Glaucoma Treatment: A Nationwide Survey by the French Glaucoma Society.
Adv Ther
September 2025
Centre d'Ophtalmologie Visis, 66000, Perpignan, France.
Introduction: Glaucoma treatment predominantly involves the use of topical anti-glaucoma eye drops, with patient adherence influenced by individual preferences. This study aimed to assess these preferences and highlight the importance of personalized treatment approaches among ophthalmologists.
Methods: This French multicenter, cross-sectional study involved 21 ophthalmologists-members of the Board of Directors of the French Society of Glaucoma-from both public and private practices, who distributed a standardized questionnaire to their patients with glaucoma.
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFThe impact of obesity and overweight on rheumatoid arthritis patients: real-world insights from a biologic and targeted synthetic DMARDs registry.
Rheumatol Int
September 2025
Department of Physical Medicine and Rehabilitaton, Ankara Bilkent City Hospital, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Türkiye, Turkey.
The Impact of Obesity and Overweight on Rheumatoid Arthritis Patients: Real-World Insights from a Biologic and Targeted Synthetic DMARDs Registry. The management of rheumatoid arthritis (RA) has advanced with biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). However, obesity, a common comorbidity, impacts treatment and disease progression efficacy.
View Article and Find Full Text PDF[The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma].
Vestn Oftalmol
September 2025
OOO Diagnosticheskij tsentr Zreniye, Saint Petersburg, Russia.
Objective: This study evaluated the effect of sequential therapy with different dosages of Mexidol on the stabilization of glaucomatous optic neuropathy (GON) in patients with primary open-angle glaucoma (POAG).
Material And Methods: The study included 80 patients (160 eyes) with stage II and III POAG, randomized into three groups comparable by age, gender, and distribution of glaucoma stage. All patients received sequential therapy with Mexidol (14 days parenterally followed by 90 days orally).